| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Nortrachelogenin targets multiple cellular pathways involved in inflammation, viral replication, and cancer cell proliferation. The compound has been shown to inhibit viral replication, making it a potential antiviral agent. Its anti-inflammatory effects are mediated through the modulation of inflammatory cytokine production and signaling pathways. The compound's anticancer activity is attributed to its ability to induce apoptosis and inhibit cell proliferation.
|
|---|---|
| ln Vitro |
In cell-free biochemical systems, Nortrachelogenin exhibits antiviral activity against various viruses. The compound's ability to inhibit viral enzymes such as proteases or polymerases can be assessed in cell-free enzymatic assays. Its anti-inflammatory activity can be evaluated by measuring its effects on purified inflammatory mediators or signaling components. The compound's antioxidant activity can be assessed using free radical scavenging assays.
|
| ln Vivo |
In cell-based assays, Nortrachelogenin exhibits antiviral effects by inhibiting viral replication in infected cells. The compound's anti-inflammatory effects are evaluated by measuring the inhibition of pro-inflammatory cytokine production in immune cells. Its anticancer activity is assessed by measuring cell viability, proliferation, and apoptosis in cancer cell lines. The compound can induce apoptosis and inhibit cell proliferation through various mechanisms.
|
| Enzyme Assay |
The cell-free assay for antiviral activity involves measuring the inhibition of viral enzymes such as proteases or polymerases. The compound is incubated with the purified enzyme and substrate, and the activity is measured using spectrophotometric or fluorometric methods. The IC50 is determined from dose-response curves. Anti-inflammatory activity can be assessed using cell-free assays measuring the inhibition of inflammatory mediators or signaling components.
|
| Cell Assay |
Cell-based assays for Nortrachelogenin involve culturing relevant cell lines and treating them with the compound at concentrations ranging from 0.1 to 100 μM. Antiviral activity is assessed by measuring viral replication using qRT-PCR or plaque assays. Anti-inflammatory effects are assessed by measuring cytokine production in stimulated immune cells. Anticancer activity is assessed by measuring cell viability using MTT or CCK-8 assays, and apoptosis is evaluated by Annexin V staining or caspase activity assays.
|
| Animal Protocol |
There is no established animal experimental protocol for Nortrachelogenin specifically. As a natural lignan with antiviral, anti-inflammatory, and anticancer activities, the compound could potentially be evaluated in animal models of viral infection, inflammation, and cancer. Typical studies involve administration of the compound to mice via oral or intraperitoneal routes.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Nortrachelogenin have not been extensively reported. As a lignan with a molecular weight of approximately 374.4 g/mol, the compound would be expected to have moderate oral bioavailability and tissue penetration. The compound is typically metabolized by the liver and gut microbiota. Further pharmacokinetic studies would be required for therapeutic development.
|
| Toxicity/Toxicokinetics |
Nortrachelogenin is intended for research use only and lacks established toxicity profiles for therapeutic applications. Standard laboratory safety precautions should be observed when handling this natural product. As a compound with diverse biological activities, it may have effects on multiple cellular processes. Standard toxicity studies would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Wikstromol has been reported in Trachelospermum asiaticum, Daphne odora, and other organisms with relevant data. See also: Wikstromol (note moved to).
Nortrachelogenin is a research-grade natural product supplied for antiviral, anti-inflammatory, and anticancer research. It is not an approved pharmaceutical and has no clinical trial history. The compound is a natural lignan also known as (-)-Wikstromol. This product is intended for research use only. |
| Molecular Formula |
C20H22O7
|
|---|---|
| Molecular Weight |
374.38
|
| Exact Mass |
374.136
|
| CAS # |
34444-37-6
|
| Related CAS # |
(+)-Nortrachelogenin;61521-74-2
|
| PubChem CID |
99938
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
609.2±50.0 °C at 760 mmHg
|
| Flash Point |
217.3±23.6 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.630
|
| Source |
Originated from plants: other families
|
| LogP |
0.92
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
27
|
| Complexity |
513
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC(C=C1C[C@@](O)(C(OC2)=O)[C@H]2CC3=CC(OC)=C(C=C3)O)=C(C=C1)O
|
| InChi Key |
ZITBJWXLODLDRH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H22O7/c1-25-17-8-12(3-5-15(17)21)7-14-11-27-19(23)20(14,24)10-13-4-6-16(22)18(9-13)26-2/h3-6,8-9,14,21-22,24H,7,10-11H2,1-2H3
|
| Chemical Name |
3-hydroxy-3,4-bis[(4-hydroxy-3-methoxyphenyl)methyl]oxolan-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~133.6 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.34 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.34 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 1.25 mg/mL (3.34 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6711 mL | 13.3554 mL | 26.7108 mL | |
| 5 mM | 0.5342 mL | 2.6711 mL | 5.3422 mL | |
| 10 mM | 0.2671 mL | 1.3355 mL | 2.6711 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
